Factors Influencing Clinical Trial Site Selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study)

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights click here. By clicking the "Download button" you agree to the terms of our Privacy Policy.

The SAT-EU study group, an independent non-profit collaborative initiative, supported by the European Forum for Good Clinical Practice (EFGCP) and several other trade and not-for profit organisations, release the results of a survey of 458 professionals representing clinical research organizations (CROs), academic clinical trial units (CTUs), and the biopharmaceutical industry in 34 countries.

The research paper found considerable variability in the perceived receptivity of countries to undertake clinical trials, with Germany, United Kingdom, and the Netherlands consistently rated the best trial markets. This led the authors to suggest the usefulness of a best practice audit of provisions governing clinical trials in these countries. "The case for action rests on the realization that evidence-based policy is indeed possible in this arena. Learning from what is working successfully will facilitate the road to creating a more welcoming environment for clinical research in Europe," the authors concluded.

Have Your Say
Rate this feature and give us your feedback in the comments section below